文献速递乳腺癌支持与姑息治疗

乳腺癌幸存者激素治疗后糖尿病风险:病例队列研究

Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study.
PubMed 文献 · J Clin Oncol · 2018-04-24

该病例队列研究纳入2002至2012年确诊的原发性非转移性浸润性乳腺癌女性幸存者2,246例,随机抽取20%亚队列,识别全部糖尿病病例,采用加权Cox回归估计风险比。平均随访5.9年,324例发生糖尿病;结论认为活动性激素治疗是乳腺癌幸存者糖尿病的显著危险因素,但不应因此停药,可通过生活方式干预降低风险。

要点

  • 激素治疗与乳腺癌幸存者糖尿病风险升高相关(HR 2.40)。
  • 芳香化酶抑制剂的糖尿病风险高于他莫昔芬(HR 4.27 vs 2.25)。
  • 不应因糖尿病风险停用激素治疗,可考虑生活方式干预。

核心结论

  • 活动性激素治疗是乳腺癌幸存者糖尿病的显著危险因素。
  • 激素治疗的生存获益大于风险,因此不建议停药,针对生活方式改变的预防策略可能将风险降至最低。

研究设计与样本

  • 病例队列研究,从Leumit健康基金招募2002至2012年确诊的原发性非转移性浸润性乳腺癌女性幸存者2,246例。
  • 基线随机抽取20%亚队列,并识别全部糖尿病病例;采用加权Cox比例风险回归模型估计调整后的风险比及95%CI。

主要发现

  • 2,246例乳腺癌幸存者中,平均随访5.9年期间324例发生糖尿病。
  • 以死亡为竞争风险计算的糖尿病粗累积发生率为20.9%(95%CI 18.3%–23.7%)。

临床怎么用

  • 对接受激素治疗的乳腺癌幸存者应关注糖尿病风险,尤其是使用芳香化酶抑制剂者。
  • 不应因糖尿病风险停用激素治疗,可建议通过生活方式调整等预防策略降低糖尿病风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Breast cancer treatments have been associated with an increased risk of multiple health-related adverse outcomes, but the relationship with diabetes remains unclear. This study investigated the association between hormone therapy and diabetes risk in breast cancer survivors. Patients and Methods We performed a case-cohort study of 2,246 female survivors recruited from the Leumit health care fund who were diagnosed with primary nonmetastatic invasive breast cancer in 2002 through 2012. A 20% random subcohort was sampled at baseline, and all diabetes cases were identified. Adjusted hazard ratios (HRs) with 95% CIs were estimated by weighted Cox proportional hazards regression models. Results Of 2,246 breast cancer survivors, 324 developed diabetes over a mean follow-up of 5.9 years. The crude cumulative incidence of diabetes that accounted for death as a competing risk was 20.9% (95% CI, 18.3% to 23.7%). In multivariable-adjusted models, hormone therapy was associated with increased diabetes risk (HR, 2.40; 95% CI, 1.26 to 4.55; P = .008). The hazard for tamoxifen use (HR, 2.25; 95% CI, 1.19 to 4.26; P = .013) was less pronounced than the use of aromatase inhibitors (HR, 4.27, 95% CI, 1.42 to 12.84; P = .010). Conclusion Active hormone therapy is a significant risk factor of diabetes among breast cancer survivors. Although cessation of treatment is not recommended because the survival benefits of hormone therapy outweigh the risks, preventive strategies aimed at lifestyle modifications may minimize the risk.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hamood R, Hamood H, Merhasin I, et al. Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study. J Clin Oncol. 2018. PMID: 29688833. doi:10.1200/JCO.2017.76.3524

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。